Prediction: Eli Lilly Will Trade at This Price in a Year

Quick Read

• Retatrutide's 19% value nonaccomplishment information pushed LLY to a 52-week high, and 4 consecutive EPS beats marque the $1,500 optimistic people achievable.

• AZN's elecoglipron delivered lone 12% value nonaccomplishment successful Phase 3 versus retatrutide's 19%, leaving Lilly good up successful the contention for GLP-1 dominance.

• TD Cowen projects LLY captures 62% of the $150 cardinal 2030 GLP-1 market, with 4 directors buying shares adjacent $950 this spring.

• Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Eli Lilly didn't marque the cut. Grab the names FREE today.

Eli Lilly (NYSE:LLY) is yet acting similar a trillion-dollar drugmaker again. After a brutal agelong successful precocious 2025 and a wobbly commencement to this year, the banal punched done caller 52-week highs connected retatrutide Phase 3 information that analysts telephone perchance first-line for obesity. The banal trades astatine $1,149.15 with a one-year summation of 50.31%, yet YTD is lone 7.29%. Can LLY deed $1,500 wrong 12 months?

What's Holding Eli Lilly Back successful 2026

Shares roseate 21.37% successful the past period and 6.19% successful the past week, but YTD trails the one-year fig due to the fact that investors spent Q1 worrying astir China NRDL pricing pressure, $584M successful IPR&D charges from 4 acquisitions, and 340B restrictions.

AstraZeneca (NASDAQ:AZN)'s elecoglipron entering Phase 3 added competitory pressure, though it showed lone 11.8% value nonaccomplishment versus retatrutide's astir 19%. Beta is simply a placid 0.517, truthful earlier volatility reflected net sound alternatively than wide marketplace moves. That explains wherefore diligent superior is pushing the banal backmost toward $1,500.

Wall Street Sees 6% Upside. That's Too Cautious

Consensus people is $1,215.10, with 6 Strong Buys, 18 Buys, 5 Holds, 1 Sell and 1 Strong Sell. That works retired to 77% bullish, yet implied upside is lone azygous digits. Our basal lawsuit sits astatine $1,295.73 (12.76% upside) with 90% confidence, optimistic lawsuit $1,499.61, blimpish $1,074.25. Analysts person chased this banal for 4 consecutive quarters of net beats.

Q1 2026 EPS of $8.55 versus $6.79 estimated was a 25.9% surprise. Earnings maturation drove meaningful tailwind successful our 247Factor, and bullishness keeps building. Targets are stale.

The Path to $1,500 Per Share

Reaching $1,500 from $1,149.15 requires a 30.5% gain. With guardant EPS of $35.46, $1,500 implies a guardant P/E of 42x. Our basal lawsuit embeds an implied aggregate of 39x, truthful the people needs lone astir 3 turns of further aggregate expansion. That is achievable.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Eli Lilly didn't marque the cut. Grab the names FREE today.